Associated tags: TSX, CPH, Hospital, Privacy, Substance-related disorder, Intellectual property, COVID-19, Insurance, Hope, Coronavirus, Interim, Fine chemical, Isotretinoin, Pharmaceutical industry, FDA
Locations: ONTARIO, CANADA, UNITED STATES
NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Cipher Pharmaceuticals Inc. (TSX: CPH; OTCQX: CPHRF), a specialty pharmaceutical company, has qualified to trade on the OTCQX® Best Market.
Key Points:
- NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Cipher Pharmaceuticals Inc. (TSX: CPH; OTCQX: CPHRF), a specialty pharmaceutical company, has qualified to trade on the OTCQX® Best Market.
- Cipher Pharmaceuticals Inc. upgraded to OTCQX from the Pink® market.
- Cipher Pharmaceuticals Inc. begins trading today on OTCQX under the symbol “CPHRF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com .
- Craig Mull, Interim Chief Executive Officer of Cipher commented, “Today’s announcement is an important milestone for Cipher.
Retrieved on:
Thursday, November 10, 2022
Hospital,
Substance-related disorder,
III,
Yoy,
Intellectual property,
Marketing,
Risk,
Conversation,
Interim,
Partnership,
Webcast,
Telephone,
Adoption,
Hope,
Depreciation,
Financial statement,
Mission statement,
Management,
Goal,
Coronavirus,
Compliance,
EBITDA,
CFO,
Company,
Privacy,
Adjustment,
EPS,
Psoriasis,
Growth,
CPH,
TSX,
Tax,
SEDAR,
Insurance,
Industry,
Acquisition,
COVID-19,
MISSISSAUGA,
Income,
Weapon,
Bookkeeping,
Pharmaceutical industry,
Bank,
Isotretinoin,
Cipher,
Q3 These factors have combined to drive a meaningful increase in profitability in the third quarter, underlined by a 252% increase in earnings per share."
Key Points:
- These factors have combined to drive a meaningful increase in profitability in the third quarter, underlined by a 252% increase in earnings per share."
- In August, Cipher bolstered its management team with the appointment of senior financial executive Bryan Jacobs as Chief Financial Officer.
- My commitment is simple, to support the continued and demonstrated profitability of Cipher, as well as a focus on growing the business.
- Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products.
Retrieved on:
Monday, September 19, 2022
Risk,
Time,
Indian stock exchange,
TSX,
COVID-19,
Substance-related disorder,
Hope,
Privacy,
Company,
Acquisition,
Compliance,
Intellectual property,
Industry,
Goal,
Coronavirus,
Insurance,
CPH,
Marketing,
Hospital,
ATS,
Toronto Stock Exchange,
Canadian Securities Exchange,
Security (finance),
Reinsurance,
Cipher MISSISSAUGA, ON, Sept. 19, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of Cipher's intention to commence a normal course issuer bid ("NCIB") for its common shares (the "Common Shares").
Key Points:
- MISSISSAUGA, ON, Sept. 19, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of Cipher's intention to commence a normal course issuer bid ("NCIB") for its common shares (the "Common Shares").
- The price which Cipher will pay for any Common Shares will be the market price at the time of acquisition.
- During that timeframe, Cipher repurchased and cancelled 1,541,445 Common Shares at an average price of approximately $2.22 per Common Share.
- Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products.
Retrieved on:
Thursday, August 11, 2022
Intellectual property,
Interim,
Industry,
CFO,
Commerce,
Substance-related disorder,
Technology,
CA,
Growth,
TSX,
Hospital,
Hope,
Compliance,
Marketing,
Risk management,
Bachelor,
COVID-19,
Company,
Acquisition,
CPA,
Coronavirus,
Risk,
Privacy,
Goal,
Insurance,
CPH,
Adoption,
Management OAKVILLE, ON, Aug. 11, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the appointment of senior finance executive Bryan Jacobs as Chief Financial Officer ("CFO") effective August 15, 2022.
Key Points:
- OAKVILLE, ON, Aug. 11, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the appointment of senior finance executive Bryan Jacobs as Chief Financial Officer ("CFO") effective August 15, 2022.
- Craig Mull, Interim CEOcommented on the appointment, "I am delighted to announce the addition of Mr. Jacobs to Cipher's executive team.
- Bryan's extensive experience in M&A and strategic leadership, will help fortify our management capabilities and drive our next phase of growth.
- Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products.
Retrieved on:
Thursday, August 11, 2022
Telephone,
Psoriasis,
Degenerative disease,
TSX,
Adjustment,
Plasma protein binding,
Marketing,
Sun,
EBITDA,
CDN,
Food,
SEDAR,
Industry,
Management,
American,
Partnership,
Tax,
Safety,
Eflornithine,
Privacy,
Webcast,
Rheumatoid arthritis,
Regulation of tobacco by the U.S. Food and Drug Administration,
Intellectual property,
Interim,
Substance-related disorder,
Growth,
Hospital,
Compliance,
European,
Income,
Moberg,
COVID-19,
Acquisition,
IFRS,
Coronavirus,
Tirofiban,
Goal,
Mission statement,
Onychomycosis,
FDA,
Hope,
Conversation,
Company,
Depreciation,
Risk,
Financial statement,
Insurance,
CPH,
III,
Adoption,
Weapon,
Cryptocurrency,
Pharmaceutical industry,
Fossil fuel,
Online gambling,
Mobile phone,
Bookkeeping,
MISSISSAUGA,
Isotretinoin,
IQVIA,
Isotretinoin (All figures are in U.S. dollars)
Key Points:
- (All figures are in U.S. dollars)
Strong balance sheet with $24.2 million in cash at June 30, 2022
MISSISSAUGA, ON, Aug. 11, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three and six month periods endedJune 30, 2022.
- Craig Mull, Interim CEO commented,"We are pleased to report that Cipher delivered another strong quarter, generating positive net income and cash from operating activities.
- Cipher will hold a conference call onAugust 12, 2022, at8:30 a.m. (ET)to discuss its financial results and other corporate developments.
- Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products.
Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products.
Key Points:
- Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products.
- Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products either directly inCanadaor indirectly through partners inCanada, the U.S., andSouth America.
- For more information, visit www.cipherpharma.com .
Privacy,
Intellectual property,
Industry,
FDA,
COVID-19,
Risk,
Hope,
TSX,
CPH,
Compliance,
CEO,
Insurance,
Health Canada,
Hospital,
Growth,
Marketing,
Interim,
CML,
Acquisition,
Board,
Coronavirus,
Substance-related disorder,
Goal,
Pharmaceutical industry,
Cipher,
Company Company founder and long-standing director Dr. John Mull decided not to stand for re-election to the Company's Board.
Key Points:
- Company founder and long-standing director Dr. John Mull decided not to stand for re-election to the Company's Board.
- Craig Mull, Interim CEOcommented, "As the founder and former CEO of Cipher, Dr. Mull has been instrumental in the growth of the Company.
- Dr. Mull also played a key role helping to capitalize the Company, which set it on the path for success.
- Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products.
CPH,
Telephone,
Company,
Eflornithine,
Conversation,
Mission statement,
EBITDA,
Regulation of tobacco by the U.S. Food and Drug Administration,
Food,
Depreciation,
Webcast,
Sun Pharma,
Moberg,
Goal,
Insurance,
SEDAR,
Tax,
Coronavirus,
Risk,
March 31,
Privacy,
COVID-19,
Marketing,
Adjustment,
TSX,
Tirofiban,
FDA,
Hope,
Industry,
Sun,
Substance-related disorder,
Partnership,
Intellectual property,
Compliance,
Hospital,
Management,
Financial statement,
Onychomycosis,
IFRS,
Adoption,
Acquisition,
Growth,
Interim,
Degenerative disease,
Weapon,
Online gambling,
Pharmaceutical industry,
Fine chemical,
Renewable energy,
Mobile phone,
Bookkeeping,
Isotretinoin,
MISSISSAUGA,
IQVIA,
Isotretinoin Our strong results have been driven by our reduced cost structure in addition to improved distribution and supply agreements."
Key Points:
- Our strong results have been driven by our reduced cost structure in addition to improved distribution and supply agreements."
- During the first quarter, Cipher announced an extension of the distribution and supply agreement with Sun Pharmaceutical Industries ("Sun Pharma") through December 31, 2026.
- This extension will provide Cipher with an additional four years of visibility into stable revenue and cashflow on the isotretinoin portfolio.
- Cipher will hold a conference call onMay 13, 2022, at8:30 a.m. (ET)to discuss its financial results and other corporate developments.
Adoption,
Market capitalization,
Company,
Interim,
Moberg,
OMX,
Marketing,
Terbinafine,
Substance-related disorder,
Coronavirus,
Compliance,
Risk,
Hospital,
CDN,
Privacy,
Food,
Onychomycosis,
TSX,
Nasdaq Stockholm,
Industry,
Goal,
Hope,
COVID-19,
Regulation of tobacco by the U.S. Food and Drug Administration,
Intellectual property,
CRO,
CPH,
FDA,
Insurance,
Acquisition,
Patient,
Partnership,
Pharmaceutical industry,
Fine chemical,
IQVIA The randomized, multicenter, vehicle-controlled Phase 3 study will include approximately 350 patients in North America.
Key Points:
- The randomized, multicenter, vehicle-controlled Phase 3 study will include approximately 350 patients in North America.
- The study design builds on the experience gained from the previous Phase 3 studies.
- Moberg Pharma will cooperate with the same CRO, lead investigator and successful sites from the previous North American study.
- "We are pleased to see the continued progress that Moberg is making to commercialize MOB-015," said Craig Mull, Interim CEO of Cipher.
Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products.
Key Points:
- Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products.
- Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products either directly inCanadaor indirectly through partners inCanada, the U.S., andSouth America.
- For more information, visit www.cipherpharma.com .
